The cancer therapy developer has now collected more than $240m altogether, having completed a series C round that included Roche Venture Fund.
US-based immuno-oncology therapy developer Arch Oncology closed a series C round featuring Roche Venture Fund, the corporate venturing arm of pharmaceutical firm Roche, at $105m on Tuesday.
Cowen Healthcare Investments, 3×5 Partners and Eventide Asset Management co-led the round, which included Adage Capital Management, Point72 Asset Management, Avego Healthcare Capital, FMB Research, Lightchain, RiverVest Venture Partners and Broadfin Holdings.
Formerly known as Tioma Therapeutics, Arch Oncology is developing antibody therapies to treat cancer patients with solid tumours or haematologic malignancies.…
